Conspectus
The rise of multidrug resistant bacteria has
significantly compromised
our supply of antibiotics and poses an alarming medical and economic
threat to society. To combat this problem, it is imperative that new
antibiotics and treatment modalities be developed, especially those
toward which bacteria are less capable of developing resistance. Peptide
natural products stand as promising candidates to meet this need as
bacterial resistance is typically slow in response to their unique
modes of action. They also have additional benefits including favorable
modulation of host immune responses and often possess broad-spectrum
activity against notoriously treatment resistant bacterial biofilms.
Moreover, nature has provided a wealth of peptide-based natural products
from a range of sources, including bacteria and fungi, which can be
hijacked in order to combat more dangerous clinically relevant infections.
This Account highlights recent advances in the total synthesis
and development of a range of peptide-based natural product antibiotics
and details the medicinal chemistry approaches used to optimize their
activity.
In the context of antibiotics with potential to treat
Gram-positive
bacterial infections, this Account covers the synthesis and optimization
of the natural products daptomycin, glycocin F, and alamethicin. In
particular, the reported synthesis of daptomycin highlights the utility
of on-resin ozonolysis for accessing a key kynurenine residue from
the canonical amino acid tryptophan. Furthermore, the investigation
into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal
linkage to a N-acetyl-d-glucosamine (GlcNAc)
sugar, which is otherwise O-linked in its native
form.
For mycobacterial infections, this Account covers the
synthesis
and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin
A. The synthesis of callyaerin A, in particular, highlighted the importance
of a (Z)-2,3-diaminoacrylamide motif for antimicrobial
activity against Mycobacterium tuberculosis, while
the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic
acid (AHMOD) residue.
Lastly, this Account covers lipopeptide
antibiotics bearing activity
toward Gram-negative bacterial infections, namely, battacin and paenipeptin
C. In both cases, optimization of the N-terminal lipid tails led to
the identification of analogues with potent activity toward Escherichia coli and Pseudomonas aeruginosa.